新型免疫检查点Siglec-15表达与老年结直肠癌预后相关性研究

doi:10.3969/j.issn.1003-9198.2024.07.006

实用老年医学 ›› 2024, Vol. 38 ›› Issue (7): 669-673.doi: 10.3969/j.issn.1003-9198.2024.07.006

新型免疫检查点Siglec-15表达与老年结直肠癌预后相关性研究

丁润, 许里, 杨俊荣, 毛圆, 朱一丹, 梁国栋

210031 江苏省南京市,南京医科大学第四附属医院普外科(丁润); 病理科(杨俊荣); 肿瘤科(毛圆);
210009 江苏省南京市,江苏省肿瘤医院病理科(许里);
210024 江苏省南京市,南京医科大学附属老年医院消化内科(朱一丹,梁国栋)

收稿日期:2023-08-18 发布日期:2024-07-23
通讯作者: 梁国栋, Email:rongchuan82@qq.com
基金资助:
国家自然科学基金面上项目(82073389)

Association between the expression of a novel check point Siglec-15 and the prognosis of elderly patients with colorectal cancer

DING Run, XU Li, YANG Junrong, MAO Yuan, ZHU Yidan, LIANG Guodong

Department of General Surgery(DING Run); Department of Pathology(YANG Junrong); Department of Oncology(MAO Yuan),the Fourth Affiliated Hospital of Nanjing Medical University, Nanjing 210031, China; Department of Pathology, Jiangsu Cancer Hospital, Nanjing 210009, China(XU Li);
Department of Gastroenterology,Geriatric Hospital of Nanjing Medical University, Nanjing 210024, China(ZHU Yidan, LIANG Guodong)

Received:2023-08-18 Published:2024-07-23
Contact: LIANG Guodong,Email:rongchuan82@qq.com

摘要/Abstract

摘要： 目的检测Siglec-15在老年结直肠癌中的表达情况及其与结直肠癌主要临床病理指标及预后的关系。方法在6例新鲜结直肠癌及癌旁组织上行一步法定量聚合酶链式反应(qPCR)检测,在组织芯片上(60例老年结直肠癌标本及癌旁对照标本)进行免疫组化检测,使用Cox回归分析并绘制Kaplan-Meier生存曲线探讨老年结直肠癌病人预后的影响因素。结果 qPCR及免疫组化结果均显示,结直肠癌组织中的Siglec-15表达明显高于癌旁组织(P=0.002,0.019)。Siglec-15的表达与老年结直肠癌病人的性别(P=0.037)、肿瘤部位(P=0.040)、淋巴结转移(P=0.037)及TNM分期(P=0.003)相关。COX回归分析和Kaplan-Meier生存曲线表明,Siglec-15表达(HR=2.39),肿瘤分化(HR=3.81)及远处转移(HR=9.53)是老年结直肠癌病人预后的影响因素(均P＜0.05)。结论 Siglec-15在结直肠癌组织中异常高表达且与老年结肠癌的临床病理特征相关。Siglec-15可作为老年结直肠癌总体生存期的预测指标。

关键词: 老年人, 结直肠癌, Siglec-15, 定量聚合酶链式反应, 免疫组化, 总生存期

Abstract: Objective To examine the expression of Sialic acid-binding immunoglobulin-like lectins(Siglec)-15 in the elderly patients with colorectal cancer(CRC) and to investigate the relationship of the expression of Siglec-15 with the clinical characteristics and the prognosis of CRC. Methods One-step quantitative polymerase chain reaction(qPCR) test was used in 6 fresh CRC samples as well as the corresponding non-cancerous tissue samples and tissue microarrays,and 60 elderly CRC samples and non-cancerous samples were detected by immunohistochemistry analysis. Cox regression and Kaplan-Meier survival analysis were conducted to evaluate the prognostic parameters in this elderly patients with CRC. Results The results of qPCR test and immunohistochemistry analysis showed that the expression of Siglec-15 in CRC tissues was significantly higher than that in paracancerous tissues(P=0.002,0.019,respectively). Moreover, the expression level of Siglec-15 protein in CRC was significantly related to gender(P=0.037), tumor location(P=0.040),lymph node metastasis(P=0.037) and TNM stage(P=0.003). Cox regression and Kaplan-Meier survival analysis showed that high Siglec-15 expression(HR=2.39),tumor differentiation (HR=3.81), distant metastasis(HR=9.53) were the influencing factors in the elderly patients with CRC(P＜0.05). Conclusions Siglec-15 is highly expressed in the CRC tissue, and is correlated with clinicopathological features of CRC. Siglec-15 may serve as a novel prognostic factor for the elderly patients with CRC.

Key words: aged, colorectal cancer, Siglec-15, quantitative polymerase chain reaction, immunohistochemistry, overall survival

中图分类号:

R 735.3

丁润, 许里, 杨俊荣, 毛圆, 朱一丹, 梁国栋. 新型免疫检查点Siglec-15表达与老年结直肠癌预后相关性研究[J]. 实用老年医学, 2024, 38(7): 669-673.

DING Run, XU Li, YANG Junrong, MAO Yuan, ZHU Yidan, LIANG Guodong. Association between the expression of a novel check point Siglec-15 and the prognosis of elderly patients with colorectal cancer[J]. Practical Geriatrics, 2024, 38(7): 669-673.

参考文献

[1] YANG B, LV Y, SHI O, et al. The global burden of colorectal cancer attributable to high plasma glucose in 204 countries and territories, 1990-2019: an analysis of the Global Burden of Disease Study [J]. Public Health, 2023,217:46-53.
[2] LI N, LU B, LUO C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America [J]. Cancer lett, 2021,522:255-268.
[3] GUO L, WANG Y, YANG W, et al. Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis [J]. Gastroenterology, 2023,165(2):414-428.
[4] YU Y, PENG W. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy [J]. Cancer Biol Med, 2023,20(5):369-384.
[5] SHAFI S, AUNG T N, XIROU V, et al. Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer [J]. Lab invest, 2022,102(10):1143-1149.
[6] YANG W B, QIN C P, DU Y Q, et al. Siglec-15 promotes progression of clear renal cell carcinoma [J]. Chin Med J: Engl, 2021,134(21):2635-2637.
[7] SUN J, LU Q, SANMAMED M F, et al. Siglec-15 as an emerging target for next-generation cancer immunotherapy [J]. Clin Cancer Res, 2021,27(3):680-688.
[8] LUO X, HOU N, CHEN X, et al. High expression of NDRG3 associates with unfavorable overall survival in non-small cell lung cancer [J]. Cancer Biomark, 2018,21(2):461-469.
[9] KANG F B, CHEN W, WANG L, et al. The diverse functions of Siglec-15 in bone remodeling and antitumor responses [J]. Pharmacol Res, 2020,155:104728.
[10] XIAO X, PENG Y, WANG Z, et al. A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mphi polarization in TME [J]. Pharmacol Res, 2022,181:106269.
[11] REN X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle [J]. Cancer Biol Med, 2019,16(2):205-210.
[12] LIU W, JI Z, WU B, et al. Siglec-15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44 [J]. FEBS Lett, 2021,595(17):2290-2302.
[13] SHENG K, WU Y, LIN H, et al. Transcriptional regulation of Siglec-15 by ETS-1 and ETS-2 in hepatocellular carcinoma cells [J]. Int J Mol Sci, 2023,24(1):792.
[14] HAO J Q, NONG J Y, ZHAO D, et al. The significance of Siglec-15 expression in resectable non-small cell lung cancer [J]. Neoplasma, 2020,67(6):1214-1222.
[15] LU Z, CHENG P, HUANG F, et al. Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes [J]. J Pathol Clin Res, 2023,9(2):121-128.
[16] FUDABA H, MOMII Y, HIRAKAWA T, et al. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients [J]. Sci Rep, 2021,11(1):1206.

新型免疫检查点Siglec-15表达与老年结直肠癌预后相关性研究

Association between the expression of a novel check point Siglec-15 and the prognosis of elderly patients with colorectal cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	丛晓飞, 李铭麟, 石春来. 老年口腔衰弱与多重用药的关系及干预策略[J]. 实用老年医学, 2024, 38(9): 872-875.
[2]	李毛毛, 张飞, 沈鑫, 李洁华. 老年人口腔衰弱与跌倒关系的研究进展[J]. 实用老年医学, 2024, 38(9): 876-879.
[3]	张飞, 李毛毛, 李铭麟, 王佳贺. 老年人口腔衰弱与抑郁症的相关性研究进展[J]. 实用老年医学, 2024, 38(9): 884-888.
[4]	李江, 邱雁, 王婷, 王丹, 虞一帆, 濮玲丽, 卜玲. 老年肺腺癌病人术前全身免疫炎症指数/血清白蛋白与临床病理特征的相关性研究[J]. 实用老年医学, 2024, 38(9): 893-896.
[5]	戴静, 崔焱. 糖化血红蛋白变异性与老年2型糖尿病病人认知功能障碍的相关性分析[J]. 实用老年医学, 2024, 38(9): 931-935.
[6]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[7]	倪红艳, 陈云, 张其兵, 马一鸣, 解成兰. 电针对老年病人下肢骨科手术围术期认知功能及炎症因子的影响[J]. 实用老年医学, 2024, 38(9): 944-947.
[8]	李晓敏, 李晓林, 栗杰, 吴蕾, 郝冉冉. 老年病人经肛双气囊小肠镜进镜效率及其影响因素研究[J]. 实用老年医学, 2024, 38(9): 958-961.
[9]	蔡荟萃, 陈燕, 王燕, 叶劲军, 朱钰颖. 多形式健康教育模式联合简易呼吸功能锻炼对老年肺癌放疗病人癌因性疲乏及遵医行为的影响[J]. 实用老年医学, 2024, 38(9): 968-972.
[10]	李湘, 栗萱, 田应选. 肺衰老与慢性呼吸系统疾病研究现状及进展[J]. 实用老年医学, 2024, 38(8): 761-765.
[11]	王小娇, 王宁, 崔宏, 叶童, 王晓明. 运动康复对老年轻中度慢性心力衰竭病人的疗效评价[J]. 实用老年医学, 2024, 38(8): 775-778.
[12]	郝世杰, 邹建鹏, 卫晨, 刘清江. 综合呼吸训练对老年帕金森病病人运动减少型构音障碍的影响[J]. 实用老年医学, 2024, 38(8): 783-787.
[13]	向超, 罗彩东. 心电图avL导联T波变化对老年冠心病病人冠脉狭窄程度的诊断价值[J]. 实用老年医学, 2024, 38(8): 788-791.
[14]	李慧颖, 蔡力力, 朱启伟. 血浆N末端脑钠肽前体对高龄左室肥厚病人预后的预测价值[J]. 实用老年医学, 2024, 38(8): 797-801.
[15]	王新平, 谢柏梅, 卫国, 叶晓莉, 赵亚芸, 谭小田. 老年特发性间质性肺炎病人血清S100A9及sCD163表达水平及临床意义[J]. 实用老年医学, 2024, 38(8): 802-807.